Feltkamp T E
Research Centre for Rheumatic Diseases Amsterdam, Arthron, Netherlands.
Ann Rheum Dis. 1996 Oct;55(10):723-7. doi: 10.1136/ard.55.10.723.
Pitfalls in the method for demonstrating antinuclear antibodies (ANA) by the indirect immunofluorescence technique are described and the use of international standard preparations outlined. Determination of the optimal border dilution dividing positive from negative results is discussed. Each laboratory is a unique setting; it must define its own method, which should rarely be changed. One should not rely on copying methods from other laboratories or commercial firms, but the reproducibility of the nuclear substrate, the conjugate, and other variables should be controlled daily by the use of a control serum which has been related to the WHO standard preparation for ANA of the homogeneous type. Since many sera contain mixtures of different ANA, the results of routine tests are best expressed in titres or expressions of the intensity of fluorescence. The ANA test using the immunofluorescence technique should be used as a screening method for other tests allowing a more defined interpretation of the ANA. Each laboratory should individually determine the border between positive and negative results. Therefore about 200 sera from local healthy controls equally distributed over sex and age, and 100 sera from local patients with definite SLE should be tested. Since the local clinicians should become acquainted with this border it should rarely be changed. Finally each laboratory should participate regularly in national and international quality control rounds, where sera known to be difficult to interpret are tested. The judgment of the organisers of these rounds should stimulate improvements in the participating laboratories.
描述了间接免疫荧光技术检测抗核抗体(ANA)方法中的陷阱,并概述了国际标准制剂的使用。讨论了确定区分阳性和阴性结果的最佳临界稀释度的方法。每个实验室都有其独特的环境;它必须确定自己的方法,而且这种方法应很少改变。不应依赖照搬其他实验室或商业公司的方法,而应通过使用与世界卫生组织均质型ANA标准制剂相关的对照血清,每天控制核底物、结合物及其他变量的可重复性。由于许多血清含有不同ANA的混合物,常规检测结果最好用滴度或荧光强度表示。使用免疫荧光技术的ANA检测应用作其他检测的筛查方法,以便对ANA进行更明确的解读。每个实验室应单独确定阳性和阴性结果之间的界限。因此,应检测约200份来自当地健康对照者的血清,按性别和年龄均匀分布,以及100份来自当地确诊SLE患者的血清。由于当地临床医生应熟悉这个界限,所以它应很少改变。最后,每个实验室应定期参加国家和国际质量控制轮次,对已知难以解读的血清进行检测。这些轮次组织者的判断应促使参与实验室改进。